Financials in USD. Standardized financial statements.
A compact view of how Ginkgo Bioworks Holdings, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Revenue? | $170.16M | $227.04M | $251.46M | $477.71M | $313.84M | $76.66M | $54.18M |
| Revenue Growth? | -25.1% | -9.7% | -47.4% | +52.2% | +309.4% | +41.5% | 0.0% |
| Cost of Revenue? | $31.52M | $38.55M | $54.01M | $204.22M | $129.69M | $15.61M | $0 |
| Gross Profit? | $138.63M | $188.49M | $197.45M | $273.49M | $184.15M | $61.05M | $54.18M |
| Gross Margin? | +81.5% | +83.0% | +78.5% | +57.3% | +58.7% | +79.6% | +100.0% |
| Operating Expenses? | $453.91M | $748.25M | $1.06B | $2.48B | $2.01B | $198.07M | $125.78M |
| Operating Income? | -$315.28M | -$559.76M | -$864.41M | -$2.21B | -$1.83B | -$137.03M | -$71.60M |
| EBITDA? | -$254.61M | -$484.39M | -$821.29M | -$2.06B | -$1.81B | -$108.58M | -$106.66M |
| Income Before Tax | -$313.60M | -$547.51M | -$892.94M | -$2.12B | -$1.84B | -$124.83M | -$119.83M |
| Income Tax Expense | -$837,000 | -$479,000 | -$71,000 | -$15.03M | -$1.48M | $1.89M | $22,000 |
| Net Income? | -$312.76M | -$547.03M | -$892.87M | -$2.10B | -$1.83B | -$126.61M | -$119.33M |
| EPS? | $-5.64 | $-10.54 | $-18.37 | $-50.15 | $-53.83 | $-3.97 | $-4.15 |
| Diluted EPS? | $-5.64 | $-10.54 | $-18.40 | $-50.20 | $-55.53 | $-4.00 | $-4.15 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality